Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma.

Hajime HosoiMitsuru MiyachiSatoshi TeramukaiSatomi SakabayashiKunihiko TsuchiyaYasumichi KuwaharaRie OnoderaKotone MatsuyamaIsao YokotaHiroshi HojoHajime OkitaJun-Ichi HataMinori HamasakiMasazumi TsuneyoshiYoshinao OdaAtsuko NakazawaMiho KatoTetsuya TakimotoKeizo HoribeJun-Ichi HaraSachiyo SuitaRyoji HanadaHidekazu MasakiMiwako NozakiHitoshi IkedaSeiji KishimotoMichio KanekoAkira KawaiYasuhide Morikawa

Published in: International journal of clinical oncology (2024)

Shorter duration therapy using vincristine, actinomycin D, and lower dose cyclophosphamide with or without radiotherapy for patients with low-risk subgroup A rhabdomyosarcoma (JRS-I LRA0401 protocol) and moderate reduction of cyclophosphamide dose for patients with low-risk subgroup B rhabdomyosarcoma (JRS-I LRB0402 protocol) did not compromise FFS.

Keyphrases

randomized controlled trial
low dose
high dose
early stage
radiation therapy
high intensity
stem cells
phase iii
squamous cell carcinoma
radiation induced
study protocol
cell therapy
replacement therapy